Head-to-head evidence
GK1-399 (formerly TTP399) vs HMS1005
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Glucokinase · full Type 2 Diabetes pipeline
GK1-399 (formerly TTP399)
Developed by vTv Therapeutics
NCT01474083 · Phase 1/2 · completed
The study was randomized, quadruple-blind, and placebo-controlled, with 248 participants across three GK1-399 dose groups and a placebo group. Its primary endpoint was a pharmacokinetic measure, a surrogate rather than a clinical outcome, and no primary endpoint results are posted.
HMS1005
Developed by Hua Medicine
NCT06498284 · Phase 1 · completed
The trial randomized participants against a matched placebo with both participants and investigators blinded, but the primary measures were safety and drug levels rather than a validated diabetes outcome like HbA1c. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The sponsor release does not cite the trial's registry number; identity rests on the matching sponsor, drug code, country, design and enrollment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: GK1-399 (formerly TTP399)'s landscape · HMS1005's landscape